Lamisil and Samsca drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lamisil (terbinafine hydrochloride) and Samsca (tolvaptan). Common drug interactions include adrenal insufficiency among females and anaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Lamisil and Samsca. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Lamisil?

Lamisil has active ingredients of terbinafine hydrochloride. It is often used in pulmonary aspergilloma (mycetoma). eHealthMe is studying from 14,080 Lamisil users. Check the latest studies of Lamisil.

What is Samsca?

Samsca has active ingredients of tolvaptan. eHealthMe is studying from 8,139 Samsca users. Check the latest studies of Samsca.



On Jul, 10, 2026

11 people who take Lamisil and Samsca together, and have interactions are studied.

Lamisil and Samsca drug interactions.

What are the common drug interactions of Lamisil and Samsca, by gender? *:

female:

  1. Adrenal insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids)
  2. Herpes zoster
  3. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
  4. Pneumonia
  5. Tinea infection (fungal skin infection)
  6. Thyroiditis subacute (inflammation of thyroid gland less severe and less durational)
  7. Fracture
  8. Right ventricular failure (right half of the heart fails to work)
  9. Upper respiratory tract inflammation
  10. Blood urea increased

male:

  1. Anaemia (lack of blood)
  2. Cellulitis (infection under the skin)
  3. Hyperuricaemia (level of uric acid in the blood that is abnormally high)
  4. Oesophageal candidiasis (fungal infection of oesophagus)
  5. Panniculitis (inflammation of the subcutaneous fat)
  6. Tinea pedis (a contagious skin infection caused by the ringworm fungus)
  7. Abscess limb (limb infection)
  8. Arthritis bacterial (form of joint disorder that involves inflammation of one or more joints due to bacterial infection)
  9. C-reactive protein increased
  10. Constipation

What are the common drug interactions of Lamisil and Samsca, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Abscess limb (limb infection)
  2. Anaemia (lack of blood)
  3. Arthritis bacterial (form of joint disorder that involves inflammation of one or more joints due to bacterial infection)
  4. C-reactive protein increased
  5. Cellulitis (infection under the skin)
  6. Constipation
  7. Erectile dysfunction
  8. Femur fracture
  9. Folliculitis (infection of hair root)
  10. Gastric polyps (abnormal growth of stomach tissue projecting from a mucous membrane)

50-59:

  1. Adrenal insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids)
  2. Herpes zoster
  3. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
  4. Pneumonia
  5. Tinea infection (fungal skin infection)
  6. Thyroiditis subacute (inflammation of thyroid gland less severe and less durational)
  7. Fracture
  8. Right ventricular failure (right half of the heart fails to work)
  9. Upper respiratory tract inflammation
  10. Anaemia (lack of blood)

60+:

  1. Acute hepatic failure
  2. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  3. Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
  4. Oedema peripheral (superficial swelling)
  5. Rash
  6. Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
  7. Sepsis (a severe blood infection that can lead to organ failure and death)
  8. Skin lesion
  9. Transaminases increased
  10. Urinary retention (the inability to completely or partially empty the bladder)

What are the existing conditions these people have? *

  1. Interstitial Lung Disease: 6 people, 54.55%
  2. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 6 people, 54.55%
  3. Urination - Painful: 3 people, 27.27%
  4. Constipation: 3 people, 27.27%
  5. High Blood Pressure: 3 people, 27.27%
  6. Oedema Peripheral (superficial swelling): 3 people, 27.27%
  7. Mycobacterium Avium Complex Infection: 3 people, 27.27%
  8. Hiv Infection: 3 people, 27.27%
  9. Hyperuricaemia (level of uric acid in the blood that is abnormally high): 3 people, 27.27%
  10. Gastritis (inflammation of stomach): 2 people, 18.18%

* Approximation only. Some reports may have incomplete information.

Do you take Lamisil and Samsca?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Lamisil and Samsca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lamisil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Samsca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lamisil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Samsca and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on terbinafine hydrochloride and tolvaptan (the active ingredients of Lamisil and Samsca, respectively), and Lamisil and Samsca (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: